DOCSLIB.ORG

Treating Opportunistic Infections Among HIV-Infected Adults and Adolescents

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Treating Opportunistic Infections Among HIV-Infected Adults and Adolescents Morbidity and Mortality Weekly Report Recommendations and Reports December 17, 2004 / Vol. 53 / No. RR-15 Treating Opportunistic Infections Among HIV-Infected Adults and Adolescents Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/ Infectious Diseases Society of America INSIDE: Continuing Education Examination department of health and human services Centers for Disease Control and Prevention MMWR CONTENTS The MMWR series of publications is published by the Epidemiology Program Office, Centers for Disease Introduction......................................................................... 1 Control and Prevention (CDC), U.S. Department of How To Use the Information in This Report .......................... 2 Health and Human Services, Atlanta, GA 30333. Effect of Antiretroviral Therapy on the Incidence and Management of OIs .................................................... 2 SUGGESTED CITATION Initiation of ART in the Setting of an Acute OI Centers for Disease Control and Prevention. Treating (Treatment-Naïve Patients) ................................................. 3 Management of Acute OIs in the Setting of ART .................. 4 opportunistic infections among HIV-infected adults and When To Initiate ART in the Setting of an OI ........................ 4 adolescents: recommendations from CDC, the National Special Considerations During Pregnancy ........................... 4 Institutes of Health, and the HIV Medicine Association/ Disease Specific Recommendations ..................................... 5 Infectious Diseases Society of America. MMWR Pneumocystis Jiroveci Pneumonia ...................................... 5 2004;53(No. RR-15):[inclusive page numbers]. Toxoplasma gondii Encephalitis ......................................... 8 Cryptosporidiosis ............................................................ 10 Centers for Disease Control and Prevention Microsporidiosis .............................................................. 12 Mycobacterium tuberculosis Disease ............................... 14 Julie L. Gerberding, M.D., M.P.H. Disseminated Mycobacterium avium Complex Disease ... 19 Director Bacterial Respiratory Disease .......................................... 21 Dixie E. Snider, M.D., M.P.H. Bacterial Enteric Disease ................................................. 23 Chief of Science Bartonellosis ................................................................... 25 Syphilis ........................................................................... 27 Tanja Popovic, M.D., Ph.D. Mucocutaneous Candidiasis ........................................... 30 (Acting) Associate Director for Science Cryptococcosis ................................................................ 32 Histoplasmosis ................................................................ 34 Coordinating Center for Health Information Coccidioidomycosis......................................................... 35 and Service* Aspergillosis ................................................................... 36 Blake Caldwell, M.D., and Edward J. Sondik, Ph.D. Cytomegalovirus Disease ................................................ 37 (Acting) Directors Herpes Simplex Virus Disease ......................................... 41 Varicella Zoster Virus Disease ......................................... 42 National Center for Health Marketing* Human Herpesvirus-8 Disease ....................................... 44 Steven L. Solomon, M.D. Progressive Multifocal Leukoencephalopathy (Acting) Director Caused by JC Virus ....................................................... 45 Human Papillomavirus Disease ....................................... 46 Division of Scientific Communications* Hepatitis C Virus Disease ................................................ 49 Hepatitis B Virus Disease ................................................ 54 John W. Ward, M.D. Geographic OIs of Special Consideration .......................... 58 (Acting) Director Penicilliosis ..................................................................... 58 Editor, MMWR Series Leishmaniasis ................................................................. 58 Suzanne M. Hewitt, M.P.A. Paracoccidioidomycosis................................................... 61 Managing Editor, MMWR Series Isosporiasis ..................................................................... 62 Chagas Disease .............................................................. 63 C. Kay Smith-Akin, M.Ed. References......................................................................... 65 Lead Technical Writer/Editor Tables ................................................................................ 86 David C. Johnson Project Editor Disclosure of Relationship Beverly J. Holland CDC, our planners, and our content specialists wish to disclose Lead Visual Information Specialist they have no financial interests or other relationships with the manufactures of commercial products, suppliers of commercial Lynda G. Cupell services, or commercial supporters. This report does not include Malbea A. LaPete any discussion of a product under investigational use. However, Visual Information Specialists this report does contain discussion of certain drugs indicated for Kim L. Bright, M.B.A. use in a nonlabeled manner and that are not Food and Drug Quang M. Doan, M.B.A. Administration (FDA) approved for such use. Each drug used in a Erica R. Shaver nonlabeled manner is identified in the text. Information included Information Technology Specialists in these guidelines might not represent FDA approval or approved labeling for the particular products or indications being discussed. * Proposed. Specifically, the terms safe and effective might not be synonymous with the FDA-defined legal standards for product approval. Vol. 53 / RR-15 Recommendations and Reports 1 Treating Opportunistic Infections Among HIV-Infected Adults and Adolescents Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America Prepared by Constance A. Benson, M.D.1 Jonathan E. Kaplan M.D.2 Henry Masur, M.D.3 Alice Pau, Pharm.D.3 King K. Holmes, M.D.4 1University of Colorado Health Sciences Center, Denver, Colorado 2CDC, Atlanta, Georgia 3National Institutes of Health, Bethesda, Maryland 4University of Washington, Seattle, Washington Summary The National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, and CDC have developed guidelines for treatment of opportunistic infections (OIs) among adults and adolescents infected with human immuno- deficiency virus (HIV). These guidelines are intended for clinicians and other health-care providers who care for HIV-infected adults and adolescents, including pregnant women; they complement companion guidelines for treatment of OIs among HIV- infected children and previously published guidelines for prevention of OIs in these populations. They include evidence-based guidelines for treatment of 28 OIs caused by protozoa, bacteria, fungi, and viruses, including certain OIs endemic in other parts of the world but that might be observed in patients in the United States. Each OI section includes information on epidemiology, clinical manifestations, diagnosis, treatment recommendations, monitoring and adverse events, management of treatment fail- ure, prevention of recurrence, and special considerations in pregnancy. Tables address drugs and doses, drug toxicities, drug interactions, adjustment of drug doses in persons with reduced renal function, and data about use of drugs in pregnant women. Introduction and interactions of the drugs to treat and prevent OIs has emerged, management strategies have evolved. New drugs have Opportunistic infections (OIs) continue to cause morbidity also become available that occupy important roles in our and mortality in patients with human immunodeficiency virus therapeutic armamentarium. (HIV)-1 infection throughout the world. Potent combination These guidelines and the accompanying guidelines, Treating antiretroviral therapy (ART) has reduced the incidence of OIs Opportunistic Infections Among HIV-Exposed and Infected for certain patients with access to care. However, certain Children, join two previous guidelines, The United States Public patients in the developed and developing world do not have Health Service-Infectious Diseases Society of America Guidelines access to care and have OIs. Other patients do not have a for the Prevention of Opportunistic Infections in Persons Infected sustained response to antiretroviral agents for multiple reasons, with the Human Immunodeficiency Virus and The Department including poor adherence, drug toxicities, drug interactions, of Health and Human Services (DHHS) Guidelines for the Use or initial acquisition of a drug-resistant strain of HIV-1. of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Therefore, OIs will continue to cause substantial morbidity The current guidelines share key features with their companion and mortality in patients with HIV-1 infection. guidelines: The therapy of OIs has changed substantially during the • They are labeled as guidelines, indicating that the recom- AIDS epidemic. As more information about efficacy, toxicity, mendations should be considered in the context of the individual patient situation and the community where The material in this report originated in the Office of the Director, the patient is being managed. National Center
Load more

Recommended publications
  • In Silico Methods for Drug Repositioning and Drug-Drug Interaction Prediction
    In silico Methods for Drug Repositioning and Drug-Drug Interaction Prediction Pathima Nusrath Hameed ORCID: 0000-0002-8118-9823 Submitted in total fulfilment of the requirements for the degree of Doctor of Philosophy Department of Mechanical Engineering THE UNIVERSITY OF MELBOURNE May 2018 Copyright © 2018 Pathima Nusrath Hameed All rights reserved. No part of the publication may be reproduced in any form by print, photoprint, microfilm or any other means without written permission from the author. Abstract Drug repositioning and drug-drug interaction (DDI) prediction are two fundamental ap- plications having a large impact on drug development and clinical care. Drug reposi- tioning aims to identify new uses for existing drugs. Moreover, understanding harmful DDIs is essential to enhance the effects of clinical care. Exploring both therapeutic uses and adverse effects of drugs or a pair of drugs have significant benefits in pharmacology. The use of computational methods to support drug repositioning and DDI prediction en- able improvements in the speed of drug development compared to in vivo and in vitro methods. This thesis investigates the consequences of employing a representative training sam- ple in achieving better performance for DDI classification. The Positive-Unlabeled Learn- ing method introduced in this thesis aims to employ representative positives as well as reliable negatives to train the binary classifier for inferring potential DDIs. Moreover, it explores the importance of a finer-grained similarity metric to represent the pairwise drug similarities. Drug repositioning can be approached by new indication detection. In this study, Anatomical Therapeutic Chemical (ATC) classification is used as the primary source to determine the indications/therapeutic uses of drugs for drug repositioning.
    [Show full text]
  • Bacterial Superinfection of Influenza Protein-2 Expression Drives Illness in Dysregulated Macrophage-Inflammatory
    Dysregulated Macrophage-Inflammatory Protein-2 Expression Drives Illness in Bacterial Superinfection of Influenza This information is current as Caleb C. J. Zavitz, Carla M. T. Bauer, Gordon J. Gaschler, of October 3, 2021. Katie M. Fraser, Robert M. Strieter, Cory M. Hogaboam and Martin R. Stampfli J Immunol published online 11 January 2010 http://www.jimmunol.org/content/early/2010/01/11/jimmun ol.0903304 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2010/01/11/jimmunol.090330 Material 4.DC1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on October 3, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published January 11, 2010, doi:10.4049/jimmunol.0903304 The Journal of Immunology Dysregulated Macrophage-Inflammatory Protein-2 Expression Drives Illness in Bacterial Superinfection of Influenza Caleb C. J. Zavitz,* Carla M. T. Bauer,* Gordon J. Gaschler,* Katie M. Fraser,† Robert M. Strieter,‡ Cory M. Hogaboam,x and Martin R. Stampfli†,{ Influenza virus infection is a leading cause of death and disability throughout the world.
    [Show full text]
  • The Impact of Infection During Pregnancy on the Mother and Baby
    16 The Impact of Infection During Pregnancy on the Mother and Baby Heather E. Jeffery and Monica M. Lahra Infection continues to account for a major pro- ascending infection from the lower genital tract, portion of maternal, fetal, and neonatal mortality and perinatal acquisition, which includes nos- and morbidity worldwide. ocomial infection and transmission of infection In the developing world, maternal systemic via breast milk (maternal or banked milk). infections, such as pneumonia, malaria, tubercu- The impact of infection (bacterial, viral, or losis, typhoid fever, and pyelonephritis, which are other) on the mother or the fetus is dependent often functions of poverty, crowding, and malnu- on maternal and fetal factors in addition to the trition, impose health costs to the mother and pathogenic properties of the infecting agent. risks to the fetus. These risks include spontaneous Maternal factors include immune function and abortion, stillbirth, preterm labor and preterm status, anatomical factors, and comorbidity. birth, low birth weight, intrauterine growth Infecting agent factors include dose, exposure, restriction (IUGR), and infection. This is in addi- and individual virulence factors. Fetal factors tion to the rapidly escalating rates of a number of include gestational age, developmental stage, and sexually transmitted diseases, in particular, fetal immune function. Table 16.1 summarizes human immunodefi ciency virus (HIV) infection the potential impact on the fetus and neonate with its associated comorbidities. with respect to the ante-, peri-, and postnatal In the developed world, preterm birth remains periods. a major, unresolved public health issue. Intrauter- The impact of infection in pregnancy on both ine infection has been shown to play a major role mother and baby is discussed in this chapter.
    [Show full text]
  • Food Safety Labelling of Chicken to Prevent Campylobacteriosis: Consumer Expectations and Current Practices Philip D
    Allan et al. BMC Public Health (2018) 18:414 https://doi.org/10.1186/s12889-018-5322-z RESEARCH ARTICLE Open Access Food safety labelling of chicken to prevent campylobacteriosis: consumer expectations and current practices Philip D. Allan†, Chloe Palmer†, Fiona Chan, Rebecca Lyons, Olivia Nicholson, Mitchell Rose, Simon Hales and Michael G. Baker* Abstract Background: Campylobacter is the leading cause of bacterial gastroenteritis worldwide, and contaminated chicken is a significant vehicle for spread of the disease. This study aimed to assess consumers’ knowledge of safe chicken handling practices and whether their expectations for food safety labelling of chicken are met, as a strategy to prevent campylobacteriosis. Methods: We conducted a cross-sectional survey of 401 shoppers at supermarkets and butcheries in Wellington, New Zealand, and a systematic assessment of content and display features of chicken labels. Results: While 89% of participants bought, prepared or cooked chicken, only 15% knew that most (60–90%) fresh chicken in New Zealand is contaminated by Campylobacter. Safety and correct preparation information on chicken labels, was rated ‘very necessary’ or ‘essential’ by the majority of respondents. Supermarket chicken labels scored poorly for the quality of their food safety information with an average of 1.7/5 (95% CI, 1.4–2.1) for content and 1.8/ 5 (95% CI, 1.6–2.0) for display. Conclusions: Most consumers are unaware of the level of Campylobacter contamination on fresh chicken and there is a significant but unmet consumer demand for information on safe chicken preparation on labels. Labels on fresh chicken products are a potentially valuable but underused tool for campylobacteriosis prevention in New Zealand.
    [Show full text]
  • Campylobacteriosis: a Global Threat
    ISSN: 2574-1241 Volume 5- Issue 4: 2018 DOI: 10.26717/BJSTR.2018.11.002165 Muhammad Hanif Mughal. Biomed J Sci & Tech Res Review Article Open Access Campylobacteriosis: A Global Threat Muhammad Hanif Mughal* Homeopathic Clinic, Rawalpindi, Islamabad, Pakistan Received: : November 30, 2018; Published: : December 10, 2018 *Corresponding author: Muhammad Hanif Mughal, Homeopathic Clinic, Rawalpindi-Islamabad, Pakistan Abstract Campylobacter species account for most cases of human gastrointestinal infections worldwide. In humans, Campylobacter bacteria cause illness called campylobacteriosis. It is a common problem in the developing and industrialized world in human population. Campylobacter species extensive research in many developed countries yielded over 7500 peer reviewed articles. In humans, most frequently isolated species had been Campylobacter jejuni, followed by Campylobactercoli Campylobacterlari, and lastly Campylobacter fetus. C. jejuni colonizes important food animals besides chicken, which also includes cattle. The spread of the disease is allied to a wide range of livestock which include sheep, pigs, birds and turkeys. The organism (5-18.6 has% of been all Campylobacter responsible for cases) diarrhoea, in an estimated 400 - 500 million people globally each year. The most important Campylobacter species associated with human infections are C. jejuni, C. coli, C. lari and C. upsaliensis. Campylobacter colonize the lower intestinal tract, including the jejunum, ileum, and colon. The main sources of these microorganisms have been traced in unpasteurized milk, contaminated drinking water, raw or uncooked meat; especially poultry meat and contact with animals. Keywords: Campylobacteriosis; Gasteritis; Campylobacter jejuni; Developing countries; Emerging infections; Climate change Introduction of which C. jejuni and 12 species of C. coli have been associated with Campylobacter cause an illness known as campylobacteriosis is a common infectious problem of the developing and industrialized world.
    [Show full text]
  • Clindamycin with Primaquine Vs. Trimethoprim-Sulfamethoxazole
    524 Clindamycin with Primaquine vs. Trimethoprim-Sulfamethoxazole Therapy for Mild and Moderately Severe Pneumocystis carinii Pneumonia in Patients with AIDS: A Multicenter, Double-Blind, Randomized Trial (CTN 004) Emil Toma, Anona Thorne, Joel Singer, Janet Raboud, From the Department of Microbiology and Infectious Diseases, Centre Claude Lemieux, Sylvie Trottier, Michel G. Bergeron, Hospitalier de l'Universite de MontreÂal, the Immunode®ciency Chris Tsoukas, Julian Falutz, Richard Lalonde, Treatment Centre (IDTC), Montreal General Hospital, and the Royal Victoria Hospital, Montreal, and Centre Hospitalier de l'Universite du Christiane Gaudreau, Rachel Therrien, and the QueÂbec, Quebec, Quebec; and the Canadian HIV Trials Network, CTN-PCP Study Group* Vancouver, British Columbia, Canada This double-blind, randomized, multicenter trial compared clindamycin/primaquine (Cm/Prq) Downloaded from https://academic.oup.com/cid/article/27/3/524/280761 by guest on 25 September 2021 with trimethoprim-sulfamethoxazole (TMP-SMZ) as therapy for AIDS-related Pneumocystis carinii pneumonia (PCP). Forty-®ve patients received clindamycin (450 mg four times daily [q.i.d.]) and primaquine (15 mg of base/d); 42 received TMP-SMZ (320 mg/1,600 mg q.i.d. if weight of §60 kg or 240 mg/1,200 mg q.i.d. if weight of õ60 kg) plus placebo primaquine. Overall, the ef®cacy of Cm/Prq was similar to that of TMP-SMZ (success rate, 76% vs. 79%, respectively); Cm/Prq was associated with fewer adverse events (P Å .04), less steroid use (P Å .18), and more rashes (P Å .07). These differences were even greater for patients with PaO2 of ú70 mm Hg (P Å .02, P Å .04, and P Å .02, respectively).
    [Show full text]
  • Potential Association Between the Recent Increase in Campylobacteriosis Incidence in the Netherlands and Proton-Pump Inhibitor Use – an Ecological Study
    Research articles Potential association between the recent increase in campylobacteriosis incidence in the Netherlands and proton-pump inhibitor use – an ecological study M Bouwknegt ([email protected])1, W van Pelt1, M E Kubbinga1, M Weda1, A H Havelaar1,2 1. National Institute for Public Health and the Environment, Bilthoven, The Netherlands 2. Utrecht University, Utrecht, the Netherlands Citation style for this article: Bouwknegt M, van Pelt W, Kubbinga ME, Weda M, Havelaar AH. Potential association between the recent increase in campylobacteriosis incidence in the Netherlands and proton-pump inhibitor use – an ecological study. Euro Surveill. 2014;19(32):pii=20873. Available online: http://www.eurosurveillance.org/ ViewArticle.aspx?ArticleId=20873 Article submitted on 01 October 2013 / published on 14 August 2014 The Netherlands saw an unexplained increase in therefore hypothesised to facilitate gastrointestinal campylobacteriosis incidence between 2003 and 2011, infections and has been reported repeatedly in case– following a period of continuous decrease. We con- control studies as a risk factor for Campylobacter and ducted an ecological study and found a statistical asso- Salmonella infections with odds ratios between 3.5 and ciation between campylobacteriosis incidence and the 12, suggesting a substantially increased risk [4]. The annual number of prescriptions for proton pump inhib- estimated attributable fraction for PPI use in campy- itors (PPIs), controlling for the patient’s age, fresh and lobacteriosis cases was estimated at 8% in a Dutch frozen chicken purchases (with or without correction case–control study [5]. for campylobacter prevalence in fresh poultry meat). The effect of PPIs was larger in the young than in the Several European countries such as the Netherlands, elderly.
    [Show full text]
  • Guidelines for Management of Opportunistic Infections and Anti Retroviral Treatment in Adolescents and Adults in Ethiopia
    GUIDELINES FOR MANAGEMENT OF OPPORTUNISTIC INFECTIONS AND ANTI RETROVIRAL TREATMENT IN ADOLESCENTS AND ADULTS IN ETHIOPIA Federal HIV/AIDS Prevention and Control Office Federal Ministry of Health July 2007 PART I GUIDELINES FOR MANAGEMENT OF OPPORTUNISTIC INFECTIONS IN ADULTS AND ADOLESCENTS ii Table of Contents Foreword iv Acknowledgement v Acronyms and Abbreviations vi 1. Introduction 1 2. Objectives and Targets 2 2.1. Objectives 2 2.2. Targets 2 3. Management of Common Opportunistic Infections 2 4. Unit 1: Management of OI of the Respiratory System 3 1.1 Bacterial pneumonia 6 1.2 Pneumonia due to Pneumocystis jiroveci. 6 1.3 Pulmonary tuberculosis 7 1.4 Correlation of pulmonary diseases and CD4 count in HIV-infected patients 9 Unit 2: Management of GI Opportunistic Diseases 11 2.1. Dysphagia and odynophagia 11 2.2. Diarrhoea 12 2.3 Peri-anal problems 14 2.4. Peri-anal and/or genital herpes 15 Unit 3: Management of Opportunistic Diseases of the Nervous system 16 3.1. Peripheral neuropathies 17 3.2. Persistent headache with (+/-) neurological manifestations (+/-) seizure 18 3.3. Management of common CNS infections presenting with headache and/or seizure 19 3.3.1. Toxoplasmosis 19 3.3.2 Management of seizure associated with toxoplasmosis and other CNS OIs 21 3.3.3 Cryptococcosis 23 3.3.4 CNS Tuberculosis 25 Unit 4: Management of Skin Disorders 26 4.1 Aetiological Classification of Skin Disorders in HIV disease. 27 4.2 Selected skin conditions in patients with HIV infection 28 4.2.1 Seborrheic dermatitis 28 4.2.2 Pruritic Papular Eruption 29 4.2.3 Kaposi’s Sarcoma 29 Unit 5: Management of Fever 30 5.1 Selected causes of fever in AIDS patients 33 5.1.1 Malaria 33 5.1.2 Visceral Leishmaniasis 33 5.1.3 Sepsis 34 Unit 6: Some Special Conditions in OI Management 35 6.1 Initiating ART in context of an acute OI 35 6.2 When to initiate ART in context of an acute OI 36 iii Tables 1.
    [Show full text]
  • Integrating Functional GI Observations Into Toxicology Studies
    Safety Pharmacology Society Webinar Series: Safety Pharmacology Endpoints: Integration into Toxicology Studies Integrating functional GI observations into toxicology studies Jean-Pierre Valentin, PhD Louise Marks, PhD Drug Safety & Metabolism Translational Safety Alderley Park, Cheshire United Kingdom [email protected] Aims of presentation • Highlight the scope of the problem surrounding GI adverse effects in preclinical and clinical development • Present an overview of the GI system and types of GI adverse effects • Highlight current Regulatory Guidance for assessing GI liability • Discuss what we can do to help to investigate this liability more thoroughly • Summarise the available methods for assessing drug-induced changes to GI function • Describe 3 methods amenable to inclusion on toxicology studies • Describe 4 real life examples of where GI endpoints have been used • Conclusion and discussion ImpactImpact of of adverse adverse effects effects of drugs of by organdrugs function by organthroughout function the pharmaceutical throughout life cycle the pharmaceutical life cycle Phase ‘Nonclinical’ Phase I Phase I-III Phase III/ Post- Post- Marketing Marketing Marketing Information: Causes of Serious ADRs Causes of ADRs on label Serious ADRs Withdrawal from attrition attrition sale Source: Car (2006) Sibille et al. Olson et al. BioPrint® (2006) Budnitz et al. Stevens & Baker (1998) (2000) (2006) (2008) Sample size: 88 CDs stopped 1,015 subjects 82 CDs stopped 1,138 drugs 21,298 patients 47 drugs Cardiovascular:
    [Show full text]
  • DHFR Inhibitors: Reading the Past for Discovering Novel Anticancer Agents
    molecules Review DHFR Inhibitors: Reading the Past for Discovering Novel Anticancer Agents Maria Valeria Raimondi 1,*,† , Ornella Randazzo 1,†, Mery La Franca 1 , Giampaolo Barone 1 , Elisa Vignoni 2, Daniela Rossi 2 and Simona Collina 2,* 1 Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, via Archirafi 32, 90123 Palermo, Italy; [email protected] (O.R.); [email protected] (M.L.F.); [email protected] (G.B.) 2 Drug Sciences Department, Medicinal Chemistry and Pharmaceutical Technology Section, University of Pavia, via Taramelli 12, 27100 Pavia, Italy; [email protected] (E.V.); [email protected] (D.R.) * Correspondence: [email protected] (M.V.R.); [email protected] (S.C.); Tel.: +390-912-389-1915 (M.V.R.); +390-382-987-379 (S.C.) † These Authors contributed equally to this work. Academic Editors: Simona Collina and Mariarosaria Miloso Received: 25 February 2019; Accepted: 20 March 2019; Published: 22 March 2019 Abstract: Dihydrofolate reductase inhibitors are an important class of drugs, as evidenced by their use as antibacterial, antimalarial, antifungal, and anticancer agents. Progress in understanding the biochemical basis of mechanisms responsible for enzyme selectivity and antiproliferative effects has renewed the interest in antifolates for cancer chemotherapy and prompted the medicinal chemistry community to develop novel and selective human DHFR inhibitors, thus leading to a new generation of DHFR inhibitors. This work summarizes the mechanism of action, chemical, and anticancer profile of the DHFR inhibitors discovered in the last six years. New strategies in DHFR drug discovery are also provided, in order to thoroughly delineate the current landscape for medicinal chemists interested in furthering this study in the anticancer field.
    [Show full text]
  • Opportunistic Infections Moorine Sekadde, Mbchb Heidi Schwarzwald, MD, MPH
    HIV Curriculum for the Health Professional Opportunistic Infections Moorine Sekadde, MBchB Heidi Schwarzwald, MD, MPH Objectives Overview 1. Define opportunistic infections (OIs) in people with Many people living with human immunodeficiency virus human immunodeficiency virus (HIV)/AIDS. (HIV)/AIDS acquire diseases that also affect otherwise 2. Describe primary prophylaxis to prevent OIs in healthy people. In such cases, HIV-infected patients people with HIV/AIDS. may have a more severe disease course than uninfected 3. Evaluate the clinical manifestations of bacterial, people or may develop symptoms that uninfected viral, parasitic, and fungal OIs in people with HIV/ people do not. However, HIV-infected people are also AIDS. susceptible to opportunistic infections (OIs), which 4. Describe the treatment for bacterial, viral, parasitic, are infections caused by organisms that in a healthy and fungal OIs in people with HIV/AIDS. host would not cause significant disease. This module 5. Review specific interventions that can decrease the discusses both types of infection. The most common OIs development of OIs in people with HIV/AIDS. vary with geographic location. This module will give a broad overview of the concepts of preventing OIs and Key Points will discuss the most commonly diagnosed diseases worldwide. The module will cover specific diseases, how to 1. An OI is caused by organisms that would not recognize them, and which medicines are recommended produce significant disease in a person with a well- to treat them. Treatment recommendations are based functioning immune system. on available information and research. Not every 2. People with HIV/AIDS are susceptible to OIs because recommendation will be feasible in every setting.
    [Show full text]
  • Influenza Infection Leads to Increased Susceptibility to Subsequent
    Influenza Infection Leads to Increased Susceptibility to Subsequent Bacterial Superinfection by Impairing NK Cell Responses in the Lung This information is current as of September 29, 2021. Cherrie-Lee Small, Christopher R. Shaler, Sarah McCormick, Mangalakumari Jeyanathan, Daniela Damjanovic, Earl G. Brown, Petra Arck, Manel Jordana, Charu Kaushic, Ali A. Ashkar and Zhou Xing J Immunol 2010; 184:2048-2056; Prepublished online 18 Downloaded from January 2010; doi: 10.4049/jimmunol.0902772 http://www.jimmunol.org/content/184/4/2048 http://www.jimmunol.org/ Supplementary http://www.jimmunol.org/content/suppl/2010/01/19/jimmunol.090277 Material 2.DC1 References This article cites 40 articles, 12 of which you can access for free at: http://www.jimmunol.org/content/184/4/2048.full#ref-list-1 by guest on September 29, 2021 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2010 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Influenza Infection Leads to Increased Susceptibility to Subsequent Bacterial Superinfection by Impairing NK Cell Responses in the Lung Cherrie-Lee Small,*,†,‡ Christopher R.
    [Show full text]